NTLA (intelliatx.com) Company Future Sales Volume

Graphic logo of Intellia Therapeutics Inc (NTLA)

Intellia Therapeutics (NTLA) leads the in vivo CRISPR editing segment as it awaits key trial results for NTLA-2001 and NTLA-2002. These developments are based on proprietary patents and support from US medical centers. The company's projected sales levels demonstrate forecast dynamics, where the value of 0.05 serves as the current metric. Environmental policy focuses on the safe disposal of chemicals and the rational use of laboratory resources.

NTLA - Intellia Corp Company Future Revenue over the range 07/04/2022 - 11/18/2026

Financial and market metric breakdowns for Intellia (NTLA)

Comprehensive company analysis:NTLA Intellia Therapeutics
Signature product of Intellia Therapeutics Inc

Fundamental analysis of this indicator allows for risk minimization by assessing the ability of Intellia Therapeutics (NTLA) to monetize CRISPR genome-editing developments for amyloidosis therapy. This metric aggregates operational changes into projected revenue; therefore, the firm's planned sales level reflects the balance between market share expansion and the risk of excessive working capital freeze within the innovation pipeline.

Competitor analysis for Intellia Therapeutics

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Company Future Sales Volume 10x Genomics TXG|Stoke Therapeutics - Company Future Sales Volume|BioLife Solutions Inc (BLFS) - Company Expected Sales Volume|wavelifesciences.com - Projected Sales Volume|Maze Therapeutics Corp (MAZE) - Company Future Sales Volume|SION: Projected Sales Volume|Company Revenue Forecast PRME|Company Projected Revenue Taysha Gene Therapies|Company Revenue Forecast QURE (uniQure)|Company Projected Revenue MeiraGTx (MGTX)|REGENXBIO Corp - Company Revenue Forecast|Company Projected Revenue Solid Biosciences SLDB|OCGN - Company Future Sales Volume|pacb.com - Projected Sales Volume|Benitec (BNTC) - Company Future Sales Volume|DSGN: Projected Sales Volume|RCKT - Company Future Sales|FDMT: Company Future Sales|Company Revenue Forecast LXEO (lexeotx.com)|Company Projected Revenue Korro Bio Inc. (KRRO)|Company Projected Revenue Volume EDIT|Projected Sales Volume SLN (Silence Therapeutics PLC)|Company Future Revenue PRQR|CDXS - Company Projected Revenue|SGMO (Sangamo Therapeutics) - Company Revenue Forecast|NAUT: Projected Sales Volume|Company Revenue Forecast MGX|DTIL (precisionbiosciences.com) - Projected Sales Volume|Company Revenue Forecast GBIO (Generation Bio Co.)|Company Projected Revenue Boundless Bio (BOLD)|Exicure - Company Revenue Forecast|Projected Sales Volume IMNN (imunon.com)|Company Future Sales Phio Pharmaceuticals (PHIO)|MBIO: Company Future Sales Volume|Company Future Revenue RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Company Projected Revenue|APDN - Company Future Sales|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume